Allison Schmitz1, Melissa Rohrich2, William Newman3, Pamela Wolf4. 1. Mental Health Clinical Pharmacy Specialist, Fargo VA Health Care System, Fargo, North Dakota, allison.schmitz@va.gov. 2. Chief of Pharmacy Services, Fargo VA Health Care System, Fargo, North Dakota. 3. Chief of Endocrinology, Fargo VA Health Care System, Fargo, North Dakota; Professor of Medicine and Acting Chair, Department of Internal Medicine, University of North Dakota School of Medicine & Health Sciences Southeast Campus, Fargo, North Dakota. 4. Mental Health Clinical Pharmacy Specialist, Fargo VA Health Care System, Fargo, North Dakota.
Abstract
INTRODUCTION: Cardiometabolic management was evaluated in patients with diabetes and a severe mental illness that require treatment with an atypical antipsychotic. METHODS: Seventy-four patients with diabetes and a severe mental illness treated with an atypical antipsychotic from the Fargo Veterans' Affairs Health Care System were included in this retrospective study. Primary end points analyzed the change in hemoglobin A1c (Hgb A1c), blood pressure, and low-density lipoprotein (LDL) cholesterol 12 months prior to and 12 months following the initiation of an atypical antipsychotic. Secondary end points evaluated changes specific to clozapine and olanzapine. Additional secondary end points evaluated the medication management for cardiometabolic disease prior to and following atypical antipsychotic initiation. RESULTS: In the 12 months following atypical antipsychotic initiation, there were no statistically significant changes in metabolic parameters. Mean Hgb A1c increased from 6.9% to 7.2% (P = .47), mean systolic blood pressure decreased slightly from 132 to 127.8 mm Hg (P = .97), mean diastolic blood pressure decreased slightly from 79.6 to 76.6 mm Hg (P = .19), and mean LDL remained unchanged at 104.4 mg/dL (P = .92). Medications to control cardiometabolic disease increased substantially following atypical antipsychotic initiation; 35.1%, 39.2%, and 39.2% of patients were started on one or more new antihyperglycemics, antihypertensives, and statins, respectively. DISCUSSION: Patients had a significant increase in prescriptions to manage cardiometabolic disease in the 12 months following initiation of an atypical antipsychotic. Although medications to manage cardiometabolic disease increased, the actual metabolic parameters did not significantly change during the same time period.
INTRODUCTION: Cardiometabolic management was evaluated in patients with diabetes and a severe mental illness that require treatment with an atypical antipsychotic. METHODS: Seventy-four patients with diabetes and a severe mental illness treated with an atypical antipsychotic from the Fargo Veterans' Affairs Health Care System were included in this retrospective study. Primary end points analyzed the change in hemoglobin A1c (Hgb A1c), blood pressure, and low-density lipoprotein (LDL) cholesterol 12 months prior to and 12 months following the initiation of an atypical antipsychotic. Secondary end points evaluated changes specific to clozapine and olanzapine. Additional secondary end points evaluated the medication management for cardiometabolic disease prior to and following atypical antipsychotic initiation. RESULTS: In the 12 months following atypical antipsychotic initiation, there were no statistically significant changes in metabolic parameters. Mean Hgb A1c increased from 6.9% to 7.2% (P = .47), mean systolic blood pressure decreased slightly from 132 to 127.8 mm Hg (P = .97), mean diastolic blood pressure decreased slightly from 79.6 to 76.6 mm Hg (P = .19), and mean LDL remained unchanged at 104.4 mg/dL (P = .92). Medications to control cardiometabolic disease increased substantially following atypical antipsychotic initiation; 35.1%, 39.2%, and 39.2% of patients were started on one or more new antihyperglycemics, antihypertensives, and statins, respectively. DISCUSSION: Patients had a significant increase in prescriptions to manage cardiometabolic disease in the 12 months following initiation of an atypical antipsychotic. Although medications to manage cardiometabolic disease increased, the actual metabolic parameters did not significantly change during the same time period.
Authors: Anthony P Weiss; David C Henderson; Jeffrey B Weilburg; Donald C Goff; James B Meigs; Enrico Cagliero; Richard W Grant Journal: Psychiatr Serv Date: 2006-08 Impact factor: 3.084
Authors: Julie Kreyenbuhl; Faith B Dickerson; Deborah R Medoff; Clayton H Brown; Richard W Goldberg; Lijuan Fang; Karen Wohlheiter; Leena P Mittal; Lisa B Dixon Journal: J Nerv Ment Dis Date: 2006-06 Impact factor: 2.254
Authors: Stephen R Marder; Susan M Essock; Alexander L Miller; Robert W Buchanan; Daniel E Casey; John M Davis; John M Kane; Jeffrey A Lieberman; Nina R Schooler; Nancy Covell; Scott Stroup; Ellen M Weissman; Donna A Wirshing; Catherine S Hall; Leonard Pogach; Xavier Pi-Sunyer; J Thomas Bigger; Alan Friedman; David Kleinberg; Steven J Yevich; Bonnie Davis; Steven Shon Journal: Am J Psychiatry Date: 2004-08 Impact factor: 18.112
Authors: Cheryl Enger; Lisa Weatherby; Robert F Reynolds; Dale B Glasser; Alexander M Walker Journal: J Nerv Ment Dis Date: 2004-01 Impact factor: 2.254
Authors: José A Spoelstra; Ronald P Stolk; Dan Cohen; Olav H Klungel; Joëlle A Erkens; Hubertus G M Leufkens; Diederick E Grobbee Journal: J Clin Psychiatry Date: 2004-05 Impact factor: 4.384